[ad_1] Roche Holdings AG RHHBY Q3 FY22 sales reached CHF14.74 billion, down 6% Y/Y due to lower sales from COVID-19 treatments and diagnostics. “The third quarter of 2022 was particularly challenging…
[ad_1] Daré Bioscience Inc DARE announced topline efficacy results from its Phase 1/2 trial of DARE-HRT1. DARE-HRT1 is a novel, investigational intravaginal ring (IVR) designed to deliver bio-identical 17β-estradiol and bio-identical…
[ad_1] Wall Street Journal Rupert Murdoch Explores News Corp and Fox Corp Consolidation Rupert Murdoch weighed merging his media empire, News Corp NWSA and Fox Corp FOX, nearly a…
[ad_1] Investor group comprising Camac Partners LLC, Concord Investment Partners Ltd, and Leonite Capital LLC condemned Pasithea Therapeutics Corp’s KTTA recently announced the acquisition of AlloMek Therapeutics LLC. The investors, collectively the largest stockholder of…
[ad_1] Reuters Twitter Says Elon Musk Under Federal Probe Over $44B Twitter Deal, In Court Filing Tesla Inc TSLA CEO Elon Musk is reportedly under investigation by federal authorities…
[ad_1] The FDA said that there was a shortage of Adderall after intermittent manufacturing delays at Teva Pharmaceutical Industries Ltd TEVA. Adderall is indicated to treat Attention Deficit Hyperactivity Disorder…
[ad_1] Reuters Joe Biden Says Saudi Arabia Will Face’ Consequences For What They’ve Done With Russia’ President Joe Biden has reportedly said there would be “consequences” for Saudi Arabia…
[ad_1] Boeing Co’s BA deliveries rose in September to 51 airplanes, while orders rose by 90. Last month, Boeing had 51 new 737 MAX airplane orders and 45 widebody airplanes, including…
[ad_1] DICE Therapeutics Inc DICE has announced positive topline data from its Phase 1 trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17. Following four weeks of…
[ad_1] Reuters US-China Chip War: KLA Relaxes Chip Supply To China U.S. chipmaker KLA Corp’s KLAC legal department emailed China informing that it shall stop sales and service to…
[ad_1] Janssen Pharmaceutical, a unit of Johnson & Johnson JNJ, announced data from an ongoing analysis of a Phase 2a trial of guselkumab and golimumab combo therapy for ulcerative colitis. The results…
[ad_1] HC Wainwright initiated coverage on Aptorum Group Limited APM with a Buy rating and a price target of $8. The analyst is bullish on Aptorum based on three points: Promising…
[ad_1] The FDA approved a label expansion for Alnylam Pharmaceuticals Inc’s ALNY for Oxlumo (lumasiran), an RNAi therapeutic administered via subcutaneous injection, now indicated for the treatment of primary hyperoxaluria type 1 (PH1)…
[ad_1] Credit Suisse has initiated coverage on Verve Therapeutics Inc VERV with a Neutral rating and a $48 target price. Its lead assets are VERVE-101 for heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic…
[ad_1] Eliem Therapeutics Inc ELYM announced interim results from its ongoing Phase 1 trial of ETX-155 for major depressive disorder (MDD) and epilepsy. Following lower-than-expected drug exposure levels in the three…
[ad_1] Needham initiated coverage on Sight Sciences Inc SGHT with a Hold rating and no price target. The analyst warns that the recent competitive launches in the minimally invasive glaucoma surgery (MIGS) market…
[ad_1] Adamis Pharmaceuticals Corp ADMP has initiated a process to explore a range of strategic and financing alternatives. The move follows the recently announced halting of the company’s Phase 2/3 trial examining the…
[ad_1] Biohaven Pharmaceutical Holding Company Ltd BHVN announced results from a focused analysis of verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS). Verdiperstat did not statistically…
[ad_1] Alzamend Neuro Inc ALZN submitted an investigational new drug application to the FDA for its immunotherapy candidate, ALZN002. The product candidate is designed to treat mild to moderate dementia of…
[ad_1] Axcella Therapeutics AXLA reported interim results from its ongoing global Phase 2b EMMPACT study of AXA1125 for nonalcoholic steatohepatitis (NASH). At 24 weeks, Axcella said all patients taking the high…
[ad_1] One of the most-watched Alzheimer’s therapies in the clinic, Biogen Inc BIIB–Eisai Limited’s ESALY experimental lecanemab reduced clinical decline on the scale by 27% compared to the placebo at 18 months…
[ad_1] TCR2 Therapeutics Inc TCRR has announced topline results from the Phase 1 portion of the gavo-cel Phase 1/2 trial for mesothelin-expressing solid tumors. Gavo-cel demonstrated a disease control rate (DCR)…
[ad_1] by Vandana Singh, Benzinga Editor September 28, 2022 8:11 AM | 1 min read The FDA approved Thermo Fisher Scientific Inc’s TMO Oncomine Dx Target Test as a companion diagnostic (CDx)…
[ad_1] Europe’s drug makers have warned about stopping manufacturing some cheap generic medicines amid surging electricity costs. The generic drug industry lobby group, Medicines for Europe, representing Teva Pharmaceutical…
[ad_1] Eagle Pharmaceuticals Inc EGRX announced that Enalare Therapeutics Inc secured a contract for up to $50.3 million from the Biomedical Advanced Research and Development Authority (BARDA). In partnership with BARDA, ENA-001 is…